Related Experiment Video
Updated: May 8, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series
Fable Zustovich1, Alessandra Ferro, Giuseppe Lombardi
1Istituto Oncologico Veneto - IRCCS, via Gattamelata 64, 35127 Padova, Italy. fable.zustovich@ioveneto.it.
Background:
Despite the large use of bevabizumab in the treatment of primary tumors of the brain, there is only limited experience with brain metastases (BM) and no experience in the treatment of previously untreated secondary brain lesions.
Patients And Methods:
We treated patients with BM, not suitable for local treatment, with a bevacizumab-based therapy associated with chemotherapy or interferon-α, as indicated for the primary cancer type.
Results:
We studied 18 patients with BM mostly from lung and renal adenocarcinoma, and the majority of patients had a treatment-naïve brain disease. Bevacizumab was found to be effective: the response rate was 60% partial responses with 40% disease stabilizations. The progression-free survival was 14 months and the overall survival was 15 months. Moreover, bevacizumab has a high capability of providing a long-lasting clinical benefit and reducing edema.
Conclusion:
Bevacizumab for treatment of BM is feasible and the efficacy data are very encouraging.
